Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research ...

So VeriSign's still-low invested capital supports its high current ROIC. On an adjusted basis, the company's ROIC was 4.4% for 2023, with a five-year average of 3.9%, according to the data provided by ...

J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor ...

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

Silver tends to outperform the rest of the precious metals sector close to the end of a given rally. We’re not there YET.

Commodities Analysis by Sunshine Profits (Przemyslaw Radomski, CFA) covering: Gold Spot US Dollar, Silver Spot US Dollar, ...